Nucs AI

Nucs AI builds an artificial intelligence platform for oncology imaging, focused on the detection, staging and treatment response evaluation of prostate cancer from PSMA-PET/CT scans. The company was founded by oncologists, AI researchers and healthcare innovators, and describes its mission as addressing radiologist burnout and patient waiting times while improving clinician decision-making.

The company's product suite comprises three solutions: DeepPSMA, SelectPSMA and TrackPSMA, each serving detection, staging and evaluation of prostate cancer from PSMA-PET/CT imaging. Reported figures for the suite include 92% accuracy in identifying PSMA-positive lesions, scan processing in under a minute, and elimination of manual work in over 50% of cases.

Nucs AI operates across San Francisco, where it is headquartered, and Berlin, where it has its roots. The company raised $3.5m in a seed round. Its technical work spans medical imaging analysis, PSMA-PET/CT image interpretation, lesion detection and staging, and treatment response evaluation, within the broader healthcare, oncology and radiology sectors.

The team is cross-disciplinary by design, bridging clinical medicine and AI research, with an emphasis on patient outcomes and clinician empowerment.